slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study PowerPoint Presentation
Download Presentation
Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study

Loading in 2 Seconds...

play fullscreen
1 / 28

Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study - PowerPoint PPT Presentation


  • 128 Views
  • Uploaded on

Usage of Benzodiazepines or Opiates Among Members Who are in Consistent Methadone Treatment in Philadelphia. Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study. Matthew O. Hurford, M.D. Chief Medical Officer, CBH Assistant Professor, Univ. of Penn.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study' - nina-gregory


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Usage of Benzodiazepines or Opiates Among Members Who are in Consistent Methadone Treatment in Philadelphia

Community Behavioral Health (CBH) Replication of Community Care Behavioral Health (CCBH) Study

Matthew O. Hurford, M.D.

Chief Medical Officer, CBH

Assistant Professor, Univ. of Penn.

objective
Objective
  • Identify Community Behavioral Health (CBH) Members in Philadelphia who are in methadone treatment and concurrently on benzodiazepines or opiates.
data sources
Data sources
  • Anaylsis period: July 1, 2010 – September 30, 2010
  • Paid methadone clinic claims from all contracts for the analysis period.
  • Paid Medicaid pharmacy claims for the analysis period.
methodology
Methodology
  • Identify members in methadone treatment for at least ten days in Q3 2010.
  • Identify members in the above population who also filled prescriptions for benzodiazepines or opiates during the same period.
  • Generate a distribution based on methadone providers in all the contracts.
  • Generate age group, gender, and racial distributions for the above population.
  • Identify the benzodiazepines and opiates used.
  • Identify physicians and specialties to the extent possible. Although this analysis was included in the original study by CCBH, CBH’s data warehouse contains very little information of this kind. Therefore, we were unable to produce a meaningful replication of this analysis.
results
Results
  • Table 1 shows the distribution of members in methadone treatment and those with concurrent benzodiazepine or opiate prescriptions during the analysis period, by Philadelphia zip code.
results1
Results
  • Tables 2, 3, and 4 show demographics for members with concurrent methadone and benzodiazepine/opiate usage.
results2
Results
  • Table 5 shows the methadone provider distribution.
results3
Results
  • Table 6 shows the distribution of members based on whether a benzodiazepine or opiate was prescribed. (Benzo = 1 if the member had a prescription for a benzodiazepine; otherwise Benzo = 0. Opiate = 1 if the member had a prescription for an opiate; otherwise Opiate = 0.)
results4
Results
  • Tables 7 and 8 show the details of the benzodiazepines or opiates prescribed. Members had 2497 benzodiazepine prescriptions and 3067 opiate prescriptions.
comparison with ccbh data
Comparison with CCBH Data
  • CCBH shows that 45.8% of MAT patients have concurrent prescriptions for benzodiazepines or opiates.
  • CBH shows that 45.6% of MAT patients have concurrent benzodiazepine or opiate prescriptions.
comparison with ccbh data1
Comparison with CCBH Data
  • CCBH shows 44.9% of MAT patients with concurrent prescriptions for benzodiazepines or opiates are ages 18-34; for CBH that number is 31.7%.
  • CCBH shows 31.3% of patients with concurrent scripts are ages 35-50 having concurrent scripts; for CBH that number is 42.2%.
  • CCBH shows 23.5% of MAT with concurrent scripts are 51-64; for CBH that number is 25.5%.
  • CCBH shows 0.3% of MAT patients having concurrent scripts are 65 or older; for CBH that number is 0.5%.
comparison with ccbh data2
Comparison with CCBH Data
  • CCBH shows 57.6% of MAT patients having concurrent scripts are female, whereas CBH shows 58.9% of patients who have concurrent scripts are female.
  • Percentages for male patients are 42.4% and 41.1%, respectively.
comparison with ccbh data3
Comparison with CCBH Data
  • CCBH found that 7% of patients having concurrent scripts were African-American. 87.3% were Caucasian, and 5.8% fell into other racial categories.
  • CBH found that 22.5% of patients with concurrent scripts were African-American or Black, 60.7% were Caucasian, and 16.8% fell into other racial categories.
  • Note that racial categories are constructed differently in the two BH/MCOs.
comparison with ccbh data4
Comparison with CCBH Data
  • CCBH providers contributed 0.1% to 33.1% to the sample.
  • CBH providers contributed a range of 2.87% to 22.5%.
comparison with ccbh data5
Comparison with CCBH Data
  • 27.7% of CCBH’s patients with concurrent scripts had a prescription for an opiate.
  • 50.2% had a prescription for a benzo.
  • 22% had a prescription for both.
  • In CBH, 27.8% of patients with concurrent scripts had a prescription for an opiate.
  • 41.9% had a prescription for a benzo.
  • 30.3% had a prescription for both.
comparison to ccbh data
Comparison to CCBH Data
  • Of 3313 concurrent benzo scripts in CCBH, clonazepam was prescribed the most often, at 17.3%
  • The same was true for CBH, where clonazepam made up 38.4% of concurrent benzo scripts.
comparison to ccbh data1
Comparison to CCBH Data

CCBH CBH

Alprazolam 12.4% 33.7%

Lorazepam 2.7% 7.4%

Temazepam 2% 9.9%

Diazepam 1.6% 7.2%

Triazolam 0.2% 0.7%

Flurazepam <0.1% 0.4%

Chlordiazepoxide <.01% 0.3%

Oxazepam <0.1% -----

Estazolam ----- 0.3%

Clorazepate ----- <0.1%

comparison to ccbh data2
Comparison to CCBH Data
  • Of 1737 concurrent opiate scripts in CCBH, 19% were for hydrocodone.
  • 21.5% of CBH’s concurrent opiate scripts were for hydrocodone; CBH members were more likely to have scripts for oxycodone (30.2%).
comparison to ccbh data3
Comparison to CCBH Data

CCBH CBH

Oxycodone 17.6% 30.2%

Tramadol 4.7% 13.8%

Codeine 3% 14.4%

Buprenorphine 2.4% 5.7%

Methadone 1.3% 5.5%

Propoxyphene 0.8% 4.1%

Hydromorpohone 0.6% -----

Fentanyl 0.5% 1.2%

Morphine ----- 2.2%

Diphenoxylate ----- 0.9%

Meperidine ----- 0.2%

Naltrexone ----- <0.1%

Oxymorphone ----- <0.1%